Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ORY.MC
- Price
- 2.83
- Stock movement down
- -0.01 (-0.53%)
- Company name
- Oryzon Genomics SA
- Exchange
- (MC ,
- Currency
- EUR )
- Sector
- Healthcare >Biotechnology
- Markedsværdi
- 179.65M
- Ent værdi
- 197.02M
- Pris/omsætning
- 43.74
- Pris/bog
- 1.85
- Udbytte afkast
- -
- Udbyttevækst
- -
- Vekst år
- -
- FCF-udbetaling
- -
- Efterfølgende P/E
- -
- Fremtidig P/E
- 85.61
- PEG
- -
- EPS-vekst
- 14.76%
- 1 års afkast
- 45.62%
- 3 års afkast
- 4.58%
- 5 års afkast
- -2.31%
- 10 års afkast
- -
Senest opdateret: 2025-06-10
UDBYTTE
ORY.MC betaler ikke udbytte
VÆRDIANSÆTTELSE
Værdiansættelsesforhold
Loading...
Værdiansættelsesforhold-data
| Efterfølgende P/E | - |
| Pris til OCF | - |
| Pris til FCF | - |
| Pris til EBITDA | - |
| EV i forhold til EBITDA | - |
Værdiansættelse (salg/bogført værdi)
Loading...
Værdiansættelse (salg/bogført værdi)-data
| Pris til omsætning | 43.74 |
| Pris til egenkapital | 1.85 |
| EV i forhold til salg | 47.97 |
ØKONOMI
Pr. aktie
Loading...
Data pr. aktie
| Aktuelt antal aktier | 63.59M |
| EPS (TTM) | -0.06 |
| FCF pr. aktie (TTM) | - |
Resultatopgørelse
Loading...
Resultatopgørelse-data
| Omsætning (TTM) | 4.11M |
| Bruttofortjeneste (TTM) | 7.12M |
| Driftsindkomst (TTM) | -6.27M |
| Nettoindkomst (TTM) | -4.06M |
| EPS (TTM) | -0.06 |
| EPS (1 år frem) | 0.03 |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | 173.35% |
| Driftsmargin (TTM) | -152.70% |
| Fortjenstmargin (TTM) | -98.89% |
Balance
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
| Kontanter | 8.44M |
| Nettotilgodehavender | 0.00 |
| Omsætningsaktiver i alt | 0.00 |
| Goodwill | 0.00 |
| Immaterielle aktiver | 0.00 |
| Ejendomme, anlæg og udstyr | 0.00 |
| Sum aktiver | 122.66M |
| Kreditor | 0.00 |
| Kortfristet/nuværende langsigtet gæld | 0.00 |
| Summen af kortfristede forpligtelser | 0.00 |
| Sum gæld | 25.81M |
| Aktionærernes egenkapital | 96.85M |
| Materielle nettoaktiver | 0.00 |
Likviditet
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
| Likviditet fra driften (TTM) | 0.00 |
| Investeringsudgifter (TTM) | 0.00 |
| Fri pengestrøm (TTM) | 0.00 |
| Udbetalt udbytte (TTM) | 0.00 |
Finansiel indkomst
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
| Egenkapitalafkast | -4.19% |
| Afkast af aktiver | -3.31% |
| Afkast af investeret kapital | -4.19% |
| Kontant afkast af investeret kapital | - |
INFORMATION OM AKTIER
Aktiediagram
Loading...
Aktiekurs-data
| Åbning | 2.85 |
| Daglig høj | 2.88 |
| Daglig lav | 2.81 |
| Daglig volumen | 263K |
| Højeste gennem alle tider | 5.14 |
| 1 års analytiker estimat | 6.27 |
| Beta | 0.65 |
| EPS (TTM) | -0.06 |
| Udbytte pr. aktie | - |
| Ex-div dato | - |
| Næste dato for resultatpræsentation | 29 Jul 2025 |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| ORY.MC | S&P500 | |
| Nuværende prisfald fra top notering | -45.04% | -2.16% |
| Højeste prisfald | -72.76% | -56.47% |
| Højeste efterår dato | 31 Dec 2024 | 9 Mar 2009 |
| Gennemsnitlig fald fra toppen | -43.95% | -11.05% |
| Gennemsnitlig tid til nyt højdepunkt | 346 days | 12 days |
| Maks. tid til nyt højdepunkt | 2181 days | 1805 days |
OPLYSNINGER OM VIRKSOMHEDEN
Markedsværdi
179.65M
Markedsværdi kategori
Small-cap
Beskrivelse
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.
Personale
46
Hjemmeside
Investor relationer
-
SEC-indsendelser
Adm. direktør
Land
Spain
By
Aktietype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
Oryzon’s CSO, Dr. Jordi Xaus, will participate in a Panel entitled “Industry Perspectives Discussion” on June 2770-90% of PMS patients show autistic related features, including aggressionAgitation/Agg...
17. juni 2025
The European market has shown resilience with the pan-European STOXX Europe 600 Index ending 0.65% higher, buoyed by easing trade tensions and slowing inflation in key economies, which may prompt furt...
5. juni 2025
Foro MedCap 2025BIO International Convention 2025 Discovery and Development Europe 2025 MADRID and CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, OR...
27. maj 2025
Successful completion of €30 Million capital increase, with strong international demand and oversubscriptionAwarded non-refundable EU grant of €13.26 Million through the first Important Project of Com...
12. maj 2025
Approximately 15 million USDOryzon to validate epigenetic agents by applying a personalized medicine approach for rare and orphan diseasesOryzon will explore Aggression in specific subsets of Autism S...
8. maj 2025
Issued 12,765,958 new sharesPriced at €2.35 per share, representing a 15.44% discount on the 5-day VWAPStrong investor demand, with the offering significantly oversubscribed€15 million anchored by a l...
24. april 2025
New “Decision to grant” communications in Europe and JapanMADRID and CAMBRIDGE, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biophar...
21. april 2025
In combination with atezolizumab or durvalumabStudy conducted under the CRADA agreement between NCI and Oryzon MADRID and CAMBRIDGE, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (IS...
15. april 2025
In March 2025, the European market is navigating a complex landscape characterized by concerns over U.S. trade tariffs, economic growth uncertainties, and fluctuating monetary policies. Despite these ...
19. marts 2025
As European markets navigate the complexities of U.S. trade tariffs and shifting monetary policies, the pan-European STOXX Europe 600 Index recently experienced a decline amid these uncertainties. In ...
19. marts 2025
Næste side